NCT06031272 (PAUSE) is a Phase 1 clinical trial of 3BNC117-LS-J in HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

What drugs are being tested in NCT06031272?

Interventions in NCT06031272: 3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J, Placebo for 10-1074-LS-J.

What condition does NCT06031272 study?

NCT06031272 studies HIV-1-infection.

Is NCT06031272 still recruiting?

NCT06031272 is currently active, enrolled. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT06031272: PAUSE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pausing Antiretroviral Treatment Under Structured Evaluation

Active, enrolled Phase 1 Last updated 7 April 2026

What this trial tests

Phase 1 trial testing 3BNC117-LS-J in HIV-1-infection in 32 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

28 May 2024

Primary endpoint
14 October 2025

30 June 2026

Quick facts

Lead sponsor	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	32
Start date	28 May 2024
Primary completion	14 October 2025
Estimated completion	30 June 2026
Sites	9 locations across Botswana, Malawi, South Africa

Drugs / interventions tested

3BNC117-LS-J — full drug profile →
10-1074-LS-J — full drug profile →
Placebo for 3BNC117-LS-J — full drug profile →
Placebo for 10-1074-LS-J — full drug profile →

Conditions studied

HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Who can join

Adults 18 to 70, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to see if it is safe to give the study antibodies (3BNC117-LS-J and 10-1074-LS-J) by intravenous infusion to people with HIV (PWH), and to see if they cause any side effects. In addition, to see how the study antibodies affect the level of HIV in the blood when participants are not taking regular HIV treatment for an extended period. This extended period of not taking regular HIV treatment is called an analytical treatment interruption (ATI).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.
Mahomed S, Pillay K, Hassan-Moosa R, Galvão BPGV, et al · · 2025 · cited 20× · PMID 40189566 · DOI 10.1186/s12981-025-00734-8
mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.
Klotchenko S, Plotnikova M. · · 2026 · PMID 41750365 · DOI 10.3390/biom16020297

Verify or expand the search:

Other trials of 3BNC117-LS-J

Trials testing the same drug.

NCT04173819 — Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Health · Phase 1, PHASE2 · completed

Other recruiting trials for HIV-1-infection

Currently open trials in the same condition.

NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting

Other Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections trials

Trials by the same sponsor.

NCT06205589 — Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB · Phase 2 · not yet recruiting
NCT06856174 — Menopausal HT for Women Living With HIV (HoT) · Phase 4 · not yet recruiting
NCT06205602 — Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa · Phase 2 · recruiting
NCT05985642 — Observational PIC Destination Cohort · recruiting
NCT05156658 — Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06031272 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06031272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing